Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support

Research output: Contribution to journalArticlepeer-review

Abstract

Background: American Society of Clinical Oncology guidelines recommend the use of growth factor after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support. This randomized trial aims to demonstrate the noninferiority of pegfilgrastim (PEG) compared with filgrastim (FIL) after HDC. Patients and methods: Eighty patients were assigned to FIL at a daily dose of 5 μg/kg or a single fixed dose of PEG (6 mg) 1 day after PBSC. The primary end point was the duration of neutropenia both in terms of absolute neutrophil count (ANC) 0.5 × 10 9/l. Results: The mean duration of neutropenia was 6 and 6.2 days and the mean time to reach an ANC >0.5 × 109/l was 11.5 and 10.8 in the FIL and PEG group, respectively. No differences were observed in the mean time to reach an ANC >1.0 × 10 9/l (12.2 versus 12.0 days) in the incidence of fever (62% versus 56%) and of documented infections (31% versus 25%). The mean duration of antibiotic therapy was 5.7 and 4.0 days in FIL and PEG group, respectively. Conclusion: PEG is not inferior to FIL in hematological reconstitution and represents an effective alternative after HDC and PBSC.

Original languageEnglish
Pages (from-to)1482-1485
Number of pages4
JournalAnnals of Oncology
Volume21
Issue number7
DOIs
Publication statusPublished - Dec 11 2009

Keywords

  • Autologous stem cell transplantation
  • Filgrastim
  • Pegfilgrastim

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support'. Together they form a unique fingerprint.

Cite this